Showing 20 of 21 recruiting trials for “Follicular lymphoma”
Odronextamab in Low Tumor Volume Advanced FL
👨⚕️ Gottfried Von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Sep 2025View details ↗
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2025View details ↗
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
RecruitingNCT06794268 ↗
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
Zanubrutinib Combined With G-CVP in Previously Untreated FL
🏥 Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started Jan 2025View details ↗
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
👨⚕️ Pengcheng He, M.D. Ph.D., First Affiliated Hospital Xi'an Jiaotong University📍 1 site📅 Started Oct 2024View details ↗
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
👨⚕️ Chan Cheah, MBBS FRACP FRCPA DMSc, Sir Charles Gairdner Hospital (SCGH)📍 135 sites📅 Started Aug 2024View details ↗
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
RecruitingNCT06070961 ↗
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
👨⚕️ Michele Merli, MD, U.O.C Ematologia, Ospedale di Circolo, Varese📍 14 sites📅 Started May 2024View details ↗
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
👨⚕️ Clinical Trial Management, Regeneron Pharmaceuticals📍 190 sites📅 Started Dec 2023View details ↗
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
👨⚕️ Bing Xu, PhD, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Nov 2023View details ↗
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
👨⚕️ Samuel Yamshon, M.D., Weill Medical College of Cornell University📍 1 site📅 Started Nov 2023View details ↗
RecruitingNCT05899621 ↗
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
👨⚕️ Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center📍 9 sites📅 Started May 2022View details ↗
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →